|
|
|

Wednesday, August 27, 2008
Latest
Crohn's Disease Medical and Health News Headlines
|
|
Crohn's Disease Medical and Health News Headlines
|
|
|
|
|
|
|
|
|
|
|
All Recent Crohn's Disease Medical Condition News Headlines |
|
|
|
|
|
|
Grey-scale and colour doppler sonography in the evaluation of children with suspected bowel inflammation: correlation with colonoscopy and histological findings.
Grey-scale and colour Doppler sonography in the evaluation of children with suspected bowel inflammation: correlation with colonoscopy and histological findings.
Clin Radiol. 2008 Sep;63(9):968-78
Authors: Epifanio M, Baldisserotto M, Spolidoro JV, Gaiger A
AIM: To evaluate the correlation of grey-scale and colour Doppler sonography with colonoscopy and histology to detect bowel inflammation in children. MATERIAL AND METHODS: The records of 72 patients with suspected bowel inflammation were reviewed retrospectively. Patients were included in the study if sonography had been performed up to 30 days before colonoscopy. Grey-scale and colour Doppler sonography were used to evaluate bowel wall thickness and vascularity for the detection of distal bowel inflammation. Findings were correlated with colonoscopy and histological findings. The sensitivity and specificity of sonographic wall thickness to detect inflammation was determined. Spearman's coefficient (rs) was used to determine the correlation of Doppler findings with colonoscopy/histology. RESULTS: Sonograms of 372 bowel segments were evaluated and results were correlated with colonoscopy and histological findings of 352 segments. The sensitivity and specificity of sonographic bowel thickness to detect inflammation in the terminal ileum and the right colon were high; in the other segments, specificity was high but sensitivity was low. The correlation of Doppler sonography with colonoscopy and histology to detect inflammation in the terminal ileum was strong (rs: 0.84; p<0.001) and in the other segments, weak to moderate; when the interval between examinations was shorter than 10 days, the correlation was stronger in all segments. Of nine patients with abnormal small bowel sonograms but normal colonoscopies, three had Crohn's disease. CONCLUSION: Sensitivity and specificity of grey-scale sonography to detect inflammation in the terminal ileum and the right colon were high, and the correlation of Doppler with colonoscopy and histology was very strong in the same segments.
PMID: 18718226 [PubMed - in process] (Source: Clinical Radiology)...
POSTED 08/24/2008 at 05:03 AM --

|
Risks and clinical features of colorectal cancer complicating crohn's disease in japanese patients
Background and Aim: No reports on the relative risk of development of colorectal cancer (CRC) in Japanese patients with Crohn's disease (CD) have been published. The present study aimed to investigate the relative risk and the clinical features of CRC complicating CD among patients managed at Fukuoka University Chikushi Hospital, Fukuoka, Japan (a tertiary referral center for inflammatory bowel diseases).Methods: The clinical backgrounds were analyzed of 512 patients with CD who have been treated by our department during the last 20-year period (1985[ndash]2005) (total 6212.6 person years at risk). The standardized incidence ratio (SIR) refers to the relative risk of CRC in the subjects as compared with that in a sex- and age-matched healthy population.Results: There were six cases with CRC. The SIR was significantly higher (3.2-fold higher; 95% confidence interval, 1.2[ndash]6.9 P < 0.05) in the CD group than in the healthy population. The significant risk factors identified were female sex, mixed small and large bowel type, observation period over 20 years, onset of CD at less than 25 years of age, presence of anal disease, and positive history of surgery. The prognosis for the six cases with CRC was very poor (five cases died within 1.5 years).Conclusion: The risk of CRC in longstanding CD in Japan was similar to that in Western countries. The necessity of surveillance in the management of CD would also need to be discussed in the near future, especially in CD patients with anal lesions or fistulae, and are particularly important in patients with a 20-year or more history of CD. (Source: Journal of Gastroenterology and Hepatology)...
POSTED 08/23/2008 at 11:00 PM --

|
Association of vitamin d receptor gene polymorphisms in iranian patients with inflammatory bowel disease
Background and Aims: The vitamin D receptor (VDR) gene maps to a region on chromosome 12 shown to be linked to inflammatory bowel disease (IBD). Many studies have recognized the relation of VDR gene polymorphisms with inflammatory and autoimmune disorders. Determining the frequency of these polymorphisms and their possible relation with IBD can improve understandings about the genetic background of these diseases. The objective of this study was to assess the association of VDR gene polymorphisms (Apa I, Taq I, Bsm I, Fok I) with IBD in Iran.Methods: In this case control designed study 150 patients with ulcerative colitis, 80 patients with Crohn's disease and 150 Age and Sex matched healthy controls from Iranian origin were enrolled. These patients were referred to a tertiary center during a two-year period (2004[ndash]2006). Assessment of VDR gene polymorphisms was performed by the polymerase chain reaction[mdash]restriction fragment length polymorphism (PCR-RFLP) method. The genotype[ndash]phenotype association for these polymorphisms was analyzed.Results: Only the frequency of the Fok I polymorphism was significantly higher in ulcerative colitis and Crohn's groups. The frequency of the polymorphic allele f was higher in ulcerative colitis and Crohn's patients comparing with controls (P = 0.011 and P < 0.001, respectively). The f/f genotype was also significantly more frequent (P < 0.001), while the F/F genotype was less presented in Crohn's patients compared to controls (P < 0.001). No genotype[ndash]phenotype association was observed with any mutations.Conclusions: This study suggests a probable association of the Fok I polymorphism in VDR receptor gene and Crohn's susceptibility in Iranian population. (Source: Journal of Gastroenterology and Hepatology)...
POSTED 08/23/2008 at 11:00 PM --

|
An snp-guided microrna map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway.
An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway.
Cell Cycle. 2008 Aug 30;7(16)
Authors: Glinsky GV
Recent large-scale genome-wide association (GWA) studies of SNP variations captured many thousands individual genetic profiles of H. sapiens and facilitated identification of significant genetic traits which are highly likely to influence the pathogenesis of several major human diseases. Here we apply the integrative genomics principles to interrogate relationships between structural features and gene expression patterns of disease-linked SNPs, microRNAs and mRNAs of protein-coding genes in association to phenotypes of 15 major human disorders, namely bipolar disease (BD); rheumatoid arthritis (RA); coronary artery disease (CAD); Crohn's disease (CD); type 1 diabetes (T1D); type 2 diabetes (T2D); hypertension (HT); ankylosing spondylitis (AS); Graves' disease (autoimmune thyroid disease; AITD); multiple sclerosis (MS); breast cancer (BC); prostate cancer (PC); systemic lupus erythematosus (SLE); vitiligo-associated multiple autoimmune disease (VIT); and ulcerative colitis (UC). We selected for sequence homology profiling a set of approximately 250 SNPs which were unequivocally associated with common human disorders based on multiple independent studies of 220,124 individual samples comprising 85,077 disease cases and 129,506 controls. Our analysis reveals a systematic primary sequence homology/complementarity-driven pattern of associations between disease-linked SNPs, microRNAs and protein-coding mRNAs defined here as a human disease phenocode. We utilize this approach to draw SNP-guided microRNA maps of major human diseases and define a consensus disease phenocode for fifteen major human disorders. A consensus disease phenocode comprises 72 SNPs and 18 microRNAs with an apparent propensity to target mRNA sequences derived from a single protein-coding gene, KPNA1. Each of microRNAs in this elite set appears linked to at least three common human diseases and has potential protein-coding mRNA targets among the principal components of the nuclear import pathway. We confirmed the validity of our findings by analyzing independent sets of most significant disease-linked SNPs and demonstrating statistically significant KPNA1-gene expression phenotypes associated with human genotypes of CD, BD, T2D and RA populations. Our analysis supports the idea that variations in DNA sequences associated with multiple human diseases may affect phenotypes in trans via non-protein-coding RNA intermediaries interfering with functions of microRNAs and defines the nuclear import pathway as a potential major target in 15 common human disorders.
PMID: 18719369 [PubMed - as supplied by publisher] (Source: Cell Cycle)...
POSTED 08/23/2008 at 02:57 PM --

|
Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in crohn's disease: a randomized multicenter trial (lir!c-trial)
Background:
With the availability of infliximab, nowadays recurrent Crohn's disease, defined as disease refractory to immunomodulatory agents that has been treated with steroids, is generally treated with infliximab. Infliximab is an effective but expensive treatment and once started it is unclear when therapy can be discontinued. Surgical resection has been the golden standard in recurrent Crohn's disease. Laparoscopic ileocolic resection proved to be safe and is characterized by a quick symptom reduction.
The objective of this study is to compare infliximab treatment with laparoscopic ileocolic resection in patients with recurrent Crohn's disease of the distal ileum with respect to quality of life and costs.
Methods/design: The study is designed as a multicenter randomized clinical trial including patients with Crohn's disease located in the terminal ileum that require infliximab treatment following recent consensus statements on inflammatory bowel disease treatment: moderate to severe disease activity in patients that fail to respond to steroid therapy or immunomodulatory therapy. Patients will be randomized to receive either infliximab or undergo a laparoscopic ileocolic resection. Primary outcomes are quality of life and costs. Secondary outcomes are hospital stay, early and late morbidity, sick leave and surgical recurrence. In order to detect an effect size of 0.5 on the Inflammatory Bowel Disease Questionnaire at a 5% two sided significance level with a power of 80%, a sample size of 65 patients per treatment group can be calculated. An economic evaluation will be performed by assessing the marginal direct medical, non-medical and time costs and the costs per Quality Adjusted Life Year (QALY) will be calculated. For both treatment strategies a cost-utility ratio will be calculated. Patients will be included from December 2007.DiscussionThe LIR!C-trial is a randomized multicenter trial that will provide evidence whether infliximab treatment or surgery is the best treatment for recurrent distal ileitis in Crohn's disease.
Trial registration:
Nederlands Trial Register NTR1150 (Source: BMC Surgery)...
POSTED 08/21/2008 at 11:00 PM --

|
Students with inflammatory bowel disease 'need more support'
Students with Crohn's disease and ulcerative colitis find it difficult adjusting to university life, say researchers who call for more support for students with inflammatory bowel disease. (Source: MedWire News - Consumer Health)...
POSTED 08/21/2008 at 07:00 PM --

|
Depression common in bowel disease patients
People with Crohn's disease and ulcerative colitis are more likely to suffer from depression than those without inflammatory bowel disease, study results show. (Source: MedWire News - Consumer Health)...
POSTED 08/21/2008 at 05:49 PM --

|
Lack of evidence for association of primary sclerosing cholangitis and primary biliary cirrhosis with risk alleles for crohn's disease in polish patients
Background:
Numerous papers have addressed the association of mutations and polymorphisms of susceptibility genes with autoimmune inflammatory disorders. We investigated whether polymorphisms that confer susceptibility to Crohn's disease could be classified also as predisposing factors for the development of primary sclerosing cholangitis and primary biliary cirrhosis in Polish patients.
Methods:
The study included 60 patients with CD, 77 patients with PSC, of which 61 exhibited IBD (40 UC, 8 CD, and 13 indeterminate colitis), and 144 patients with PBC. All the patients were screened against Crohn's disease associating genetic polymorphisms.
The polymorphisms were chosen according to previously confirmed evidence for association with Crohn's disease, including Pro268Ser, Arg702Trp, Gly908Arg and 1007fs in NOD2/CARD15, Leu503Phe / -207G>C in SLC22A4/OCTN1 / SLC22A5/OCTN2, Arg30Gln in DLG5, Thr300Ala in ATG16L1, and Arg381Gln, His3Gln and exon-3'UTR in IL23R. Genotyping was carried out using TaqMan SNP genotyping assays.
Results:
We confirmed a strong association between three NOD2/CARD15 gene variants (Pro268Ser, OR=2.52, 95% CI=1.34 - 4.75); (Arg702Trp, OR=6.65, 95% CI=1.99 - 22.17); (1007fs, OR=9.59, 95% CI=3.94 - 23.29), and a weak association between both the protective OCTN1/OCTN2 CC haplotype (OR=0.28, 95% CI=0.08 - 0.94), and a variant of ATG16L1 gene (Thr300Ala, OR=0.468, 95% CI=0.24 - 0.90) with Crohn's disease. In contrast, none of the polymorphisms exhibited association with susceptibility to primary sclerosing cholangitis and primary biliary cirrhosis, including a group of primary sclerosing cholangitis patients with concurrent IBD.
Conclusions:
Although the clinical data indicate non-random co-occurrence of inflammatory bowel disease and primary sclerosing cholangitis, consistently with the previously published studies, no genetic association was found between the genetic variants predisposing to Crohn's disease and hepatobiliary autoimmune disorders. However, since estimation of genetic variant disproportion is limited by sample size, these negative results may also indicate that eventually shared genetic predispositions are too little to be captured by small patient groups. (Source: BioMed Central)...
POSTED 08/20/2008 at 11:00 PM --

|
[colorectal cancer] high frequency of early colorectal cancer in inflammatory bowel disease
Background and aim:
To detect precancerous dysplasia or asymptomatic cancer, patients suffering from inflammatory bowel disease often undergo colonoscopic surveillance based on American or British guidelines. It is recommended that surveillance is initiated after 8–10 years of extensive colitis, or after 15–20 years for left-sided disease. These starting points, however, are not based on solid scientific evidence. Our aim was to assess the time interval between onset of inflammatory bowel disease (IBD) and colorectal carcinoma (CRC), and subsequently evaluate how many patients developed cancer before their surveillance was recommended to commence.
Methods:
A nationwide automated pathology database (PALGA) was consulted to identify patients with IBD-associated colorectal carcinoma in seven university medical centres in The Netherlands between January 1990 and June 2006. Data were collected retrospectively from patient charts. Time intervals between onset of disease and cancer diagnosis were calculated in months.
Results:
149 patients were identified with confirmed diagnoses of IBD and CRC (ulcerative colitis n = 89/Crohn’s disease n = 59/indeterminate colitis n = 1). Taking date of diagnosis as the entry point, 22% of patients developed cancer before the 8 or 15 year starting points of surveillance, and 28% if surveillance was commenced 10 or 20 years after diagnosis for extensive or left-sided disease, respectively. Using onset of symptoms to calculate the time interval, 17–22% of patients would present with cancer prior to the surveillance starting points.
Conclusions:
These results show that the diagnosis of colorectal cancer is delayed or missed in a substantial number of patients (17–28%) when conducting surveillance strictly according to formal guidelines. (Source: Gut)...
POSTED 08/20/2008 at 11:00 PM --

|
[case reports] use of sirolimus (rapamycin) to treat refractory crohn's disease
We present the case of a 37-year-old woman with severe refractory colonic and perianal Crohn’s disease who had lost response to second-line, steroid-sparing treatments azathioprine, methotrexate and infliximab. For many such patients extensive surgery has often been considered the only option. New insights provided by the results of genome-wide association scanning in Crohn’s disease highlight autophagy, a cellular process implicated in the clearance of intracellular bacteria, as a key process in Crohn’s disease pathogeneses. Sirolimus (rapamycin) is a drug used to upregulate autophagy in cell culture in the laboratory, and in clinical practice to prevent rejection following organ transplantation due to independent immunosuppressive action. Our patient was treated with sirolimus for 6 months at a dose that maintained serum trough levels of 5 ng/ml. There was marked and sustained improvement in Crohn’s disease symptoms with the Harvey–Bradshaw index falling from 13 to 3, in serum markers of inflammation (C-reactive protein fell from 79 to 2) and endoscopic appearance. This is the first reported case of the use of sirolimus to treat Crohn’s disease. (Source: Gut)...
POSTED 08/20/2008 at 11:00 PM --

|
[postscript] crohn's-like enterocolitis associated with mycophenolic acid treatment
(Source: Gut)...
POSTED 08/20/2008 at 11:00 PM --

|
[postscript] genetic variants in the autophagy pathway contribute to paediatric crohn's disease
(Source: Gut)...
POSTED 08/20/2008 at 11:00 PM --

|
Comprehensive disease control: can we differentiate among the biologic agents in crohn's disease? (slides with transcript)
(Source: Medscape FamilyMedicine Headlines)...
POSTED 08/20/2008 at 02:25 PM --

|
Welcome and introduction: setting new treatment goals for crohn's disease in 2008 (slides with transcript)
(Source: Medscape FamilyMedicine Headlines)...
POSTED 08/20/2008 at 02:25 PM --

|
Comprehensive disease control: can we differentiate among the biologic agents in crohn's disease? (slides with audio)
(Source: Medscape FamilyMedicine Headlines)...
POSTED 08/20/2008 at 02:25 PM --

|
Welcome and introduction: setting new treatment goals for crohn's disease in 2008 (slides with audio)
(Source: Medscape FamilyMedicine Headlines)...
POSTED 08/20/2008 at 02:25 PM --

|
Clinical and genetic aspects of blau syndrome: a 25-year follow-up of one family and a literature review.
Clinical and genetic aspects of Blau syndrome: A 25-year follow-up of one family and a literature review.
Autoimmun Rev. 2008 Aug 18;
Authors: Punzi L, Furlan A, Podswiadek M, Gava A, Valente ML, De Marchi M, Peserico A
Blau syndrome (BS) is a rare familial disease transmitted as an autosomal dominant trait, characterized by arthritis, uveitis, skin rash and granulomatous inflammation. Until now BS has been observed in 136 persons belonging to 28 families as well as in 4 sporadic cases. The gene responsible for BS has recently been identified in the nucleotide-binding domain (NBD) of caspase recruitment domain (CARD15/NOD2), also involved in the pathogenesis of Crohn's disease. In addition to three missense mutations (R334Q, R334W and L469F) previously identified, a new CARD 15 mutation (E383K) has recently been described in a family followed by us for the past 25 years. The characteristics of this family which, to our knowledge, is the only one affected with BS in Italy, are the object of this manuscript. Both the proband and her daughter were originally affected with a papulonodular skin eruption and then with mild arthritis of the hands and feet. The proband, but not the daughter, complained of severe chronic bilateral uveitis, followed by glaucoma and, a few years later, by cataracts. Histological examination of skin biopsies from both subjects and a joint biopsy (daughter only), showed non-caseating granulomas with multinucleated giant cells which, at electron microscopy, revealed "comma-shaped bodies" in epithelioid cells, thought to be a marker for BS. The disease is presently well controlled with low doses of prednisone for the mother and non-steroidal anti-inflammatory drugs (NSAIDs) plus low doses of prednisone, when necessary, for the daughter. As in Crohn's disease, CARD 15/NOD2 mutation is believed to be responsible for the granulomatous autoinflammatory reactions probably triggered by microorganisms in BS.
PMID: 18718560 [PubMed - as supplied by publisher] (Source: Autoimmunity Reviews)...
POSTED 08/17/2008 at 11:00 PM --

|
Metastatic crohn's disease involving the penis
Abstract Metastatic Crohn's disease is a rare complication in Crohn's disease and there have been only several cases of metastatic
Crohn's disease involving the penis. We report one such case. A 22-year-old male student developed anal pain and alternative
constipation and diarrhea in December, 1985, followed by diarrhea and lower abdominal pain in January, 1986. He was diagnosed
as having Crohn's disease of ileocolitis type. He was admitted to our hospital in July, 1987 because of exacerbation of Crohn's
disease. He had anal tags. Soon after admission, two red swollen lesions with central ulcer and erosions were demonstrated
at the eversion of the foreskin adjacent to coronal sulcus. Histology of the lesions revealed granulomas with epithelioid
cells and giant cells. The lesion responded to a topical steroid. Eight cases of metastatic Crohn's disease involving the
penis are briefly reviewed.
Content Type Journal ArticleCategory Case ReportDOI 10.1007/BF02936961Authors
Mitsuro Chiba, Akita University School of Medicine First Department of Internal Medicine 1-1-1 Hondo 010 Akita City JapanMasahiro Iizuka, Akita University School of Medicine First Department of Internal Medicine 1-1-1 Hondo 010 Akita City JapanYasuo Horie, Akita University School of Medicine First Department of Internal Medicine 1-1-1 Hondo 010 Akita City JapanOsamu Masamune, Akita University School of Medicine First Department of Internal Medicine 1-1-1 Hondo 010 Akita City Japan
Journal Journal of GastroenterologyOnline ISSN 1435-5922Print ISSN 0944-1174
Journal Volume Volume 32
Journal Issue Volume 32, Number 6 / November, 1997 (Source: Journal of Gastroenterology)...
POSTED 08/17/2008 at 08:35 AM --

|
Managing crohn's disease in adults.
Some insight into Crohn's Disease from our clinical columnistPage: 152DOI: 10.1097/01.NT.0000303342.60358.16Authors: Burrowes, Jerrilynn D. PhD, RD, CDN (Source: Nutrition Today)...
POSTED 08/17/2008 at 05:22 AM --

|
Isis initiates clinical trial of crp drug
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced it has initiated a Phase 1 study of ISIS 353512, an antisense drug that inhibits the production of C-reactive protein (CRP). CRP levels are frequently elevated in patients with a variety of diseases including cardiovascular disease, Crohn's disease, rheumatoid arthritis and end-stage renal disease. (Source: Cardiovascular / Cardiology News From Medical News Today)...
POSTED 08/14/2008 at 03:00 AM --

|
|
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE: The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
Featured Product! |
 |
|
Total Balance
Men's Plus |
|
"The restoration and maintenance of normal organ and brain function, a strong immune system, and the balancing of hormones is the key to vibrant health and in avoiding premature-aging!" |
|
CLICK HERE for more info... |
|
|